Abstract 1876P
Background
Societal beliefs about cancer can impact how patients perceive their disease generating cancer stigma (CS) with risk of emotional distress especially in Arab countries where cancer remains a taboo. This study aimed to evaluate aspects of CS according to Tunisian cancer patients, explore risk factors and describe the impact on mental health.
Methods
The study was a cross-sectional questionnaire-based study, conducted between February and April 2023, including 100 patients treated for cancer regardless of gender, type or stage. We developed the questionnaire by adapting items from the “Cancer stigma scale” using questions grouped in three domains: impossibility of recovery, stereotypes of cancer patients and experience of social discrimination. Depression and anxiety were evaluated by using the “Hospital Anxiety and Depression Scale”.
Results
Median age was 50 years old, 75% of patients were women. On average, patients were surveyed 20.48 months after diagnosis. Patients reported at least one form of CS in 57% of cases. They believed in the impossibility of recovery after cancer experience in 47% of cases. Forty percent of patients held stereotypical views of themselves: 48% endorsed that cancer patients would have a difficult time having sexual intimacy which was the item with the highest mean (2.45) among all questions. Thirty four percent of patients reported social discrimination on grounds of cancer: by family/spouse in 31%, at the workplace in 15% and by friends/neighbors in 13% of cases. Cancer stigma was significantly more perceived by patients with low socioeconomic status (OR= 3.74 [1.42-9.82]), living in rural areas (OR=26 [3.38-205] and with advanced stage disease (OR=4.2 [1.67-10.5]). Forty percent of patients reported significant depressive symptoms and 47% significant anxiety symptoms. Patients who experienced CS were 4.27 times more likely to have depression (p <0.001) and 3.57 times more probably to be anxious (p <0.001) than patients with positive attitudes.
Conclusions
Despite increased awareness, cancer patients had high levels of CS with negative impact on mental health. These results ring the alarm bell to change societal beliefs and to help patients perceive “better” their disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05